Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Grant Support/Research Contract - Corvia Medical; Axon Therapies
• Consultant Fee/Honoraria/Speaker's Bureau - Axon Therapies; Edwards Lifesciences; Corvia Medical